Show simple item record

dc.contributor.authorMaris, JM
dc.contributor.authorSeeger, RC
dc.contributor.authorLondon, WB
dc.contributor.authorDeSantes, KB
dc.contributor.authorGadbaw, B
dc.contributor.authorYang, R
dc.contributor.authorReisfeld, RA
dc.contributor.authorGillies, SD
dc.contributor.authorShusterman, S
dc.contributor.authorKim, K
dc.contributor.authorSeo, S
dc.contributor.authorGan, J
dc.contributor.authorLorentzen, D
dc.contributor.authorKolesar, J
dc.contributor.authorHank, JA
dc.contributor.authorDelgado, DC
dc.contributor.authorSondel, Paul
dc.date.accessioned2011-08-23T19:58:57Z
dc.date.available2011-08-23T19:58:57Z
dc.date.issued2010-12-01
dc.identifier.urihttp://digital.library.wisc.edu/1793/54147
dc.descriptionPMID: 20935224en
dc.description.abstractResponse to immunocytokine (IC) therapy is dependent on natural killer cells in murine neuroblastoma (NBL) models. Furthermore, killer immunoglobulin-like receptor (KIR)/KIR-ligand mismatch is associated with improved outcome to autologous stem cell transplant for NBL. Additionally, clinical antitumor response to monoclonal antibodies has been associated with specific polymorphic-Fc?R alleles. Relapsed/refractory NBL patients received the hu14.18-IL2 IC (humanized anti-GD2 monoclonal antibody linked to human IL2) in a Children's Oncology Group phase II trial. In this report, these patients were genotyped for KIR, HLA, and FcR alleles to determine whether KIR receptor-ligand mismatch or specific Fc?R alleles were associated with antitumor response. DNA samples were available for 38 of 39 patients enrolled: 24 were found to have autologous KIR/KIR-ligand mismatch; 14 were matched. Of the 24 mismatched patients, 7 experienced either complete response or improvement of their disease after IC therapy. There was no response or comparable improvement of disease in patients who were matched. Thus KIR/KIR-ligand mismatch was associated with response/improvement to IC (P = 0.03). There was a trend toward patients with the Fc?R2A 131-H/H genotype showing a higher response rate than other Fc?R2A genotypes (P = 0.06). These analyses indicate that response or improvement of relapsed/refractory NBL patients after IC treatment is associated with autologous KIR/KIR-ligand mismatch, consistent with a role for natural killer cells in this clinical response.en
dc.titleGenotypes of NK cell KIR Receptors, Their Ligands, and Fc? Receptors in the Response of Neuroblastoma Patients to Hu14.18-IL2 Immunotherapyen
dc.typeArticleen


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record